Saturday 17 October 2026
Export BFRI’s income statement to Excel — free account
Biofrontera Inc.
BFRI Healthcare Drug Manufacturers Specialty & Generic
Biofrontera Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.7 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.9%, EPS grew 91.2%, free cash flow grew 45.6% and total debt rose 6.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
0.82
0.03
−3.53%
Follow BFRI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.27 | 0.22 | 0.14 | 0.29 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.40) | (135.19) | (2.44) | (2.79) | |
P/B ratio |
2.06 | 1.56 | 0.55 | 0.00 | |
Price to Tangible BV |
3.62 | 2.73 | 0.74 | 0.00 | |
EV/Sales |
0.27 | 0.19 | 0.10 | 0.32 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.58) | (0.88) | (0.32) | (1.00) | |
EV/FCF |
(1.58) | (0.87) | (0.32) | (1.00) | |
Quick Ratio |
0.97 | 0.93 | 1.15 | 0.51 | |
Current Ratio |
1.18 | 1.20 | 1.52 | 1.15 | |
Net Debt/EBITDA |
0.14 | 0.39 | (0.38) | (0.17) | |
Debt/Assets |
19.20% | 19.04% | 16.07% | 28.95% | |
Debt/Equity |
0.78 | 0.78 | 0.44 | (1.73) | |
Asset Turnover |
2.09 | 2.09 | 1.65 | 2.19 | |
Operating CF/Net income |
2.75 | 0.01 | (0.42) | 0.58 | |
Capex/Depreciation |
0.00 | (0.03) | 0.00 | 0.00 | |
Interest Coverage |
(4.16) | (34.56) | 37.97 | (56.56) | |
Research and Development Expense of Revenue |
3.73% | 8.93% | 4.61% | 12.22% | |
Selling, General and Administrative Expense of Revenue |
80.55% | 109.04% | 51.15% | 148.35% | |
Intangible Assets out of Total Assets |
0.11 | 0.11 | 0.09 | 0.00 | |
Share Based Compensation of Revenue |
2.19% | 3.39% | 1.69% | 3.38% | |
Graham Net Nets |
(0.46) | (0.59) | 0.00 | (0.34) | |
Graham Number |
0.00 | 0.00 | 0.00 | 2.28 | |
Earnings Yield |
(47.37%) | (119.75%) | (180.70%) | (97.66%) | |
Free Cash Flow Yield |
(64.59%) | (98.46%) | (230.48%) | (112.53%) | |
Revenue per Share |
0.93 | 0.86 | 1.68 | 0.65 | |
Operating CF per Share |
(0.13) | (0.01) | (0.23) | (0.35) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.01) | (0.23) | (0.35) | |
Cash per Share |
0.36 | 0.54 | 0.63 | 0.32 | |
Shareholders Equity per Share |
0.46 | 0.52 | 1.03 | (0.24) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.46 | 0.52 | 1.03 | (0.24) | |
Free Cash Flow |
(1.66) | (0.07) | (2.37) | (3.82) | |
Working Capital |
1.89 | 2.24 | 6.19 | 1.86 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
(5.67) | (5.56) | 0.00 | (3.58) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.75 | 3.96 | 6.30 | 3.93 | |
Average Payables |
5.15 | 5.45 | 6.93 | 5.70 | |
Average Inventory |
2.56 | 3.88 | 4.04 | 5.43 | |
Average Assets |
22.10 | 20.69 | 25.33 | 16.97 | |
Average Common Equity |
0.64 | 3.27 | 7.46 | 1.47 |
Columns are period end dates